39947.1 IP-LS

Résumé

Anti-L1CAM antibody therapy for rare diseases

Textes supplémentaires

Abstract

By combining Elthera's expert knowledge in the development of therapeutic antibodies and IOR's expertise in basic and translational research in rare cancer types, we aim to develop a new efficacious immunotherapy for patients suffering from highly aggressive malignancies.

Participants

Gunther Spohn

Wirtschaftspartner

gunther.spohn@elthera.com

Elthera AG CHE-210.870.067 Gunther Spohn Baarerstrasse 43 6300 Zug ZG CH

Francesco Bertoni

Kontaktperson

francesco.bertoni@ior.usi.ch

Institute of Oncology Research IOR Francesco Bertoni Via Chiesa 5 6500 Bellinzona TI CH

Détails du projet

Office de recherche: INNOSUISSE
Statut du projet: Abgeschlossen
Type de projet: Forschungsprojekt
Date de début: 2020-10-31
Date de fin: 2022-10-31
Coûts totaux approuvés: CHF 719638.07
Section: 60 Life Sciences
Domaine politique NABS: Industrielle Produktivität und Technologie

Disciplines de recherche

B720 General practice, medical training 100.0%